Long-Term Survival in Metastatic Melanoma Patients Treated with Sequential Biochemotherapy: Report of a Phase II Study

By Neri B.   Vannozzi L.   Fulignati C.   Pantaleo P.   Pantalone D.   Paoletti C.   Perfetto F.   Turrini M.   Mazzanti R.  

Cancer Investigation, Vol. 24, Iss. 5, 2006-06 ,pp. : 474-478

Informa Healthcare

Access to resources Recommend Favorite

Metastatic melanoma: Is biochemotherapy the future?

By Alexandrescu Doru   Dutcher Janice   Wrnik Peter  

Medical Oncology, Vol. 22, Iss. 2, 2005-06 ,pp. : 101-111

Humana Press, Inc

Access to resources Recommend Favorite

The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: Serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma

By Tas Faruk   Oguz Hilal   Argon Andaç   Duranyildiz Derya   Camlica Hakan   Yasasever Vildan   Topuz Erkan  

Medical Oncology, Vol. 22, Iss. 3, 2005-09 ,pp. : 241-246

Humana Press, Inc

Access to resources Recommend Favorite

Serum VEGF-C is associated with metastatic site in patients with malignant melanoma

By Vihinen Pia P.   Hilli Johanna   Vuoristo Meri-Sisko   Syrjänen Kari J.   Kähäri Veli-Matti   Pyrhönen Seppo O.  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 678-684

Informa Healthcare

Access to resources Recommend Favorite

Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy

By Hansen Bettina Dencker   Schmidt Henrik   von der Maase Hans   Sjoegren Pia   Agger Ralf   Hokland Marianne  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 400-405

Informa Healthcare

Access to resources Recommend Favorite